Katarína Gazdíková


Affiliation: Slovak Medical University
Country: Slovakia


  1. Egom E, Pharithi R, Hesse S, Starr N, Armstrong R, Sulaiman H, et al. Latest Updates on Lipid Management. High Blood Press Cardiovasc Prev. 2019;26:85-100 pubmed publisher
    ..The present article will review the latest updates on lipid management with emphases on the different classes of cholesterol-lowering agents and their clinical uses. ..
  2. Tibaut M, Caprnda M, Kubatka P, Sinkovic A, Valentova V, Filipova S, et al. Markers of Atherosclerosis: Part 1 - Serological Markers. Heart Lung Circ. 2019;28:667-677 pubmed publisher
    ..In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction. ..
  3. Tibaut M, Caprnda M, Kubatka P, Sinkovic A, Valentova V, Filipova S, et al. Markers of Atherosclerosis: Part 2 - Genetic and Imaging Markers. Heart Lung Circ. 2019;28:678-689 pubmed publisher
    ..With new methodologies, such as proteomics and metabolomics, discoveries of new clinically applicable biomarkers are expected. ..
  4. Mytsyk Y, Dosenko V, Borys Y, Kucher A, Gazdíková K, Büsselberg D, et al. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. Int Urol Nephrol. 2018;50:851-859 pubmed publisher
    ..1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC. ..
  5. Kubatka P, Zubor P, Büsselberg D, Kwon T, Adamek M, Petrovic D, et al. Melatonin and breast cancer: Evidences from preclinical and human studies. Crit Rev Oncol Hematol. 2018;122:133-143 pubmed publisher
    ..Melatonin alone or in combined administration seems to be appropriate drug for the treatment of early stages of breast cancer with documented low toxicity over a wide range of doses. These and other issues are also discussed. ..
  6. Mytsyk Y, Dutka I, Borys Y, Komnatska I, Shatynska Mytsyk I, Farooqi A, et al. Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade. Int Urol Nephrol. 2017;49:215-224 pubmed publisher
    ..The modality of the MRI DWI along with ADC measurement allows to reliably differentiate between the solid RCC of main histologic subtypes and grades, cystic RCC, and the benign renal lesions. ..
  7. El Hawli A, Qaradakhi T, Hayes A, Rybalka E, Smith R, Caprnda M, et al. IRAP inhibition using HFI419 prevents moderate to severe acetylcholine mediated vasoconstriction in a rabbit model. Biomed Pharmacother. 2017;86:23-26 pubmed publisher
    ..HFI419 had no effect on normal vasodilation. Our results indicate a therapeutic potential of HFI419 in reducing coronary artery vasospasm. ..
  8. Varinska L, Kubatka P, Mojzis J, Zulli A, Gazdíková K, Zubor P, et al. Angiomodulators in cancer therapy: New perspectives. Biomed Pharmacother. 2017;89:578-590 pubmed publisher
    ..In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis. ..
  9. Caprnda M, Kubatka P, Gazdíková K, Gasparova I, Valentova V, Stollárová N, et al. Immunomodulatory effects of stem cells: Therapeutic option for neurodegenerative disorders. Biomed Pharmacother. 2017;91:60-69 pubmed publisher

More Information


  1. Mytsyk Y, Dutka I, Yuriy B, Maksymovych I, Caprnda M, Gazdíková K, et al. Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI. Int Urol Nephrol. 2018;50:197-204 pubmed publisher
    ..However, the possibility of differentiation between ccRCC histologic subtypes and grades, utilizing ADC values, is limited. ..